Patents Examined by Susan M. Perkins
  • Patent number: 5264554
    Type: Grant
    Filed: January 19, 1990
    Date of Patent: November 23, 1993
    Assignee: The Blood Center of Southeastern Wisconsin, Inc.
    Inventor: Peter J. Newman
  • Patent number: 5240913
    Abstract: This invention relates to novel biologically active molecules which bind to and inhibit thrombin. These molecules comprise a catalytic site directed moiety (CSDM) of the formula ##STR1## wherein X is hydrogen or is characterized by a backbone chain consisting of from 1 to 100 atoms; R.sub.1 is selected from the group consisting of unsubstituted, monosubstituted, di-substituted and tri-substituted saturated ring structures; R.sub.2 is a bond or is characterized by a backbone chain consisting of from 1 to 5 atoms; R.sub.3 is a bond or is characterized by a backbone chain consisting of from 1 to 3 atoms; R.sub.4 is any amino acid; R.sub.5 is any L-amino acid which comprises a guanidinium- or amino-containing side chain group; R.sub.6 is a non-amide bond; and Y is characterized by a backbone chain consisting of from 1 to 9 atoms; or the formula: ##STR2## wherein R'.sub.1 is selected from the group consisting of unsubstituted, mono-substituted, di-substituted and tri-substituted ring structures; R'.sub.
    Type: Grant
    Filed: February 8, 1991
    Date of Patent: August 31, 1993
    Assignee: Biogen, Inc.
    Inventors: John M. Maraganore, Jo-Ann M. Jablonski, Paul R. Bourdon
  • Patent number: 5225533
    Abstract: A method to obtain selected individual peptides or families thereof which have a target property and optionally to determine the amino acid sequence of a selected peptide or peptides to permit synthesis in practical quantities is disclosed. In general outline, the method of the invention comprises synthesizing a mixture of randomly or deliberately generated peptides using standard synthesis techniques, but adjusting the individual concentrations of the components of a mixture of sequentially added amino acids according to the coupling constants for each amino acid/amino acid coupling. The subgroup of peptides having the target property can then be selected, and either each peptide isolated and sequenced, or analysis performed on the mixture to permit its composition to be reproduced. Also included in the invention is an efficient method to determine the relevant coupling constants.
    Type: Grant
    Filed: March 22, 1991
    Date of Patent: July 6, 1993
    Assignee: The Regents of the University of California
    Inventors: William J. Rutter, Daniel V. Santi
  • Patent number: 5212286
    Abstract: Methods, compounds and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering atrial natriuretic/vasodilator peptides to said host. Also provided are methods for producing such peptide compounds.
    Type: Grant
    Filed: June 5, 1986
    Date of Patent: May 18, 1993
    Assignee: Scios Nova Inc.
    Inventors: John A. Lewicki, Robert M. Scarborough, Jr.
  • Patent number: 5196404
    Abstract: This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18 .ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.
    Type: Grant
    Filed: July 6, 1990
    Date of Patent: March 23, 1993
    Assignees: Biogen, Inc., Health Research, Inc.
    Inventors: John M. Maraganore, John W. Fenton, II, Toni Kline
  • Patent number: 5189022
    Abstract: The present invention relates to a method of treating chronic fatigue syndrome not associated with an HIV infection. In the method of the present invention patients are administered a pharmaceutically acceptable carrier together with(1) a neuropsychiatrically effective amount of a linear peptide of formula (I):R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.6 (I)whereinR.sup.a is Ala, D-Ala or Cys-Ala-, andR.sup.6 is Thr, Thr-amide, Thr-Cys or Thr-Cys-amide,or a derivative of the peptide or a physiologically acceptable salt thereof; or(2) a neuropsychiatrically effective amount of a linear peptide of formula (II):R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II)whereinR.sup.1 is X-Y or Y when Y is Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu-, and X is Cys;R.sup.2 is Thr-, Ser- or Asp;R.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp;R.sup.4 is Tyr; andR.sup.
    Type: Grant
    Filed: May 8, 1991
    Date of Patent: February 23, 1993
    Assignee: The United States of America as represented by the Secretary of Health and Human Services
    Inventors: Thomas P. Bridge, Frederick K. Goodwin
  • Patent number: 5189146
    Abstract: The present specification describes a process by which a blood substitute (hereinafter referred to as "HemoSafe") is derived from uniformly stabilized monomers and polymers of deoxyhemoglobin in its tight (T) conformation, with oxygen affinity similar to that of human blood. Two classes of HemoSafe are derived respectively from animal-hemoglobin and human-hemoglobin. HemoSafe (animal) differs from HemoSafe (human) in that it is free of polymers in order to reduce potential immunogenicity if used in man. Both types of HemoSafe may be derived in the following manner. The stabilized deoxyhemoglobins are converted to their carbonmonoxy derivatives (CO-HemoSafe) which are then stable under pasteurization conditions to render them viral disease transmission-free. CO-HemoSafes are stable for 2 months at C. in either the solution or the freeze-dried state. For transfusion CO-HemoSafes are easily oxygenated under sterile conditions by photoconversion yielding oxy-HemoSafe.
    Type: Grant
    Filed: October 24, 1991
    Date of Patent: February 23, 1993
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence
    Inventor: Jen-Chang Hsia
  • Patent number: 5183804
    Abstract: A polypeptide comprising repeated amino acid sequences of a cell-adhesive protein represented by the formula:(Arg--Gly--Asp)nor(Tyr--Ile--Gly--Ser--Arg)nwherein n is a number ranging from 2 to 20; or a pharmaceutical acceptable salt thereof, which is valuable as an antimetastatic agent for cancer.
    Type: Grant
    Filed: June 23, 1989
    Date of Patent: February 2, 1993
    Assignee: Ichiro Azuma
    Inventors: Ikuo Saiki, Norio Nishi, Ichiro Azuma, Seiichi Tokura
  • Patent number: 5182366
    Abstract: A method of preparing a mixture of peptides having a known composition and containing a peptide of a desired amino acid sequence is disclosed. The method involves three essential steps. First a given amount of a mixture of amino acyl or peptide derivatized resin is divided into a number of pools with each pool containing an equal molar amount of the resin mixture. Second a different single amino acid is coupled to the resin mixture in each of the pools and the coupling reaction is driven to completion. The peptide mixtures in each of the pools are then mixed together to obtain a complex peptide mixture containing each peptide in retrievable and analyzable amounts. The steps can be repeated to lengthen the peptide chains and methods can be employed to retrieve the desired peptide from the mixture and carry out analyses such as the determination of the amino acid sequence.
    Type: Grant
    Filed: May 15, 1990
    Date of Patent: January 26, 1993
    Inventors: Verena D. Huebner, Daniel V. Santi
  • Patent number: 5171271
    Abstract: A medical device is provided which is coated with a polypeptide which can bind heparin and promote cellular adhesion and neurite outgrowth is provided of the formula:lys-asn-asn-gln-lys-ser-glu-pro-leu-ile-gly-arg-lys-lys-thr,leu-ile-gly-arg-lys-lys-thr,tyr-arg-val-arg-val-thr-pro-lys-glu-lys-thr-gly-pro-met-lys-glu,ser-pro-pro-arg-arg-ala-arg-val-thr,trp-gly-pro-pro-arg-ala-arg-ile, or mixtures thereof.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: December 15, 1992
    Assignee: Regents of the University of Minnesota
    Inventors: Leo T. Furcht, James B. McCarthy
  • Patent number: 5164369
    Abstract: The present invention relates to a human SP18 monomer protein-related polypeptide useful in forming a synthetic pulmonary surfactant. The present invention also relates to a method of treating neonatal respiratory distress syndrome comprising adminstering a therapeutically effective amount of synthetic pulmonary of the present invention. Further contemplated by the present invention is a composition containing human SP18 monomer and human SP18 dimer but no other pulmonary surfactant proteins. A recombinant DNA molecule capable of expressing, without post-translational proteolytic processing, mature human SP18 monomer, and methods of using the recombinant DNA molecule are also contemplated.
    Type: Grant
    Filed: January 4, 1989
    Date of Patent: November 17, 1992
    Assignee: The Scripps Research Institute
    Inventors: Charles G. Cochrane, Susan D. Revak
  • Patent number: 5164366
    Abstract: The present invention relates to novel human insulin analogues exhibiting a low ability to associate in solution, a method for the preparation of such insulin analogues, insulin preparations containing the human insulin analogues of the invention and a method of treating Diabetes Mellitus using these human insulin analogues.
    Type: Grant
    Filed: December 20, 1989
    Date of Patent: November 17, 1992
    Assignee: Novo Nordisk A/S
    Inventors: Per Balschmidt, Jens J. V. Brange
  • Patent number: 5159061
    Abstract: A peptide derivative of the formula ##STR1## wherein A is hydrogen or a hydrocarbon acyl having 2 to 18 carbon atoms which is substituted by an amino group at the .alpha.-position; B is F-Gly wherein F is a neutral .alpha.-amino acid residue, or NH-(CH.sub.2)nCO wherein n is an integer of 1 to 4; C is a neutral .alpha.-amino acid residue; and E is L-Arg or D-Arg; when A, B and C are hydrogen, Gly-Gly, and Met or Ile, respectively, E is D-Arg, or its pharmacologically acceptable salt has strong hypotensive and natriuretic activity; therefore it is useful as a therapeutic drug for hypertension, a diuretic, and a therapeutic drug for cardiac and cerebral circulatory diseases.
    Type: Grant
    Filed: September 25, 1987
    Date of Patent: October 27, 1992
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Masahiko Fujino, Mitsuhiro Wakimasu, Kohei Nishikawa
  • Patent number: 5140102
    Abstract: A novel pentadecapeptide is disclosed which is useful for the control of intestinal fluid absorption and that has the following amino acid sequence ##STR1##
    Type: Grant
    Filed: September 23, 1991
    Date of Patent: August 18, 1992
    Assignee: Monsanto Company
    Inventor: Mark G. Currie
  • Patent number: 5140009
    Abstract: The present invention relates to novel LHRH analogs. The LHRH analogs include "pseudo" hexapeptide, heptapeptide, octapeptide and nonapeptide analogs of LHRH, wherein all or some of the amino acids, 1, 2 and 3 have been eliminated and the remaining (2-9), (2-10), (3-9), (3-10), (4-9) or (4-10) peptide is linked to various carboxylic acids which take the place of amino acids 1, 2 or 3 in LHRH.
    Type: Grant
    Filed: July 10, 1990
    Date of Patent: August 18, 1992
    Assignee: Tap Pharmaceuticals, Inc.
    Inventors: Fortuna Haviv, Jonathan Greer, Christopher A. Palabrica, Timothy D. Fitzpatrick
  • Patent number: 5138037
    Abstract: The present invention relates to a process for preparing optically active synthons, in which an oxygen-silylated amino acid or peptide having a protected nitrogenous group, is activated by a non-coordinated halogenated phosphorus derivative and is condensed with an N-silyl amino acid or peptide in which the acid group is protected.
    Type: Grant
    Filed: March 5, 1991
    Date of Patent: August 11, 1992
    Assignee: Rhone-Poulenc Chimie
    Inventors: Robert Jacquier, Jean Verducci, Virginie Pevere
  • Patent number: 5138038
    Abstract: Novel protein partial degradation products obtainable from grain proteins such as wheat protein, maize protein, soya bean protein, etc., by specific degradation treatments, which are useful as a quality-improving agent for various food stuffs, a surface active agent, a dispersing agent for particles, etc.
    Type: Grant
    Filed: October 4, 1990
    Date of Patent: August 11, 1992
    Assignee: Katayama Chemical Works Co., Ltd.
    Inventors: Sakae Katayama, Atsushi Tsuda, Kenzi Hanno
  • Patent number: 5134121
    Abstract: The present invention provides both agonist and antagonist nerve growth factor peptides. The NGF blocking peptides can be used to inhibit the expression of mRNA and their encoded proteins whose expression is stimulated by NGF, such as .beta.-protein precursor and prion proteins, which proteins or their products are associated with neurodegenerative disorders, whereas the NGF agonist peptides can be used to treat neoplastic disorders such as neuroblastomas.
    Type: Grant
    Filed: January 14, 1991
    Date of Patent: July 28, 1992
    Assignee: Regents of the University of California
    Inventors: William C. Mobley, Frank M. Longo, James C. Kauer
  • Patent number: 5114923
    Abstract: The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula: ##STR1## wherein R.sup.1 is selected from the group consisting of: ##STR2## or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human NP in FIG. 6, or a composite thereof;R.sup.2 is (OH), NH.sub.2, or NR'R" wherein R' and R" are independently lower alkyl (1-4C) or is ##STR3## or the amides (NH.sub.2 or NR'R") thereof, with the proviso that if formula (1) isR.sup.
    Type: Grant
    Filed: February 2, 1990
    Date of Patent: May 19, 1992
    Assignee: California Biotechnology Inc.
    Inventors: Jeffrey J. Seilhamer, John A. Lewicki, Robert M. Scarborough, J. Gordon Porter
  • Patent number: 5112809
    Abstract: Analogs of CRF are disclosed that can be administered to achieve a substantial elevation of ACTH, .beta.-endorphin, .beta.-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone levels and/or a lowering of blood pressure over an extended period of time. One analog which has been found to be particularly preferred is: [His.sup.20, Nle.sup.21, Leu.sup.38 ]-rCRF. In the analogs, one or more of the first five N-terminals residues may be deleted or may be substituted by a peptide up to 10 amino acids long and/or by an acylating agent containing up to 7 carbon atoms. A number of other substitutions may also be made throughout the chain. These analogs or pharmaceutically or veterinarily acceptable salts thereof, dispersed in a pharmaceutically or veterinarily acceptable liquid or solid carrier, can be administered to mammels, including humans. These analogs may also be used as stimulants to elevate mood and improve memory and learning.
    Type: Grant
    Filed: November 20, 1990
    Date of Patent: May 12, 1992
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Wylie W. Vale, Jr.